Abstract: (17690 Views)
Background: The induction chemotherapy regimen for acute myeloid leukemia has evolved as once induction is
completed patients progress through the consolidation phase and achieve remission in 76% of cases. For patients
with relapsed or refractory disease, alternative chemotherapy agents are available. Monoclonal antibody therapy
with biological agents, such as the immunotoxin gemtuzumab ozogamicin has been used to induce remission in
relapsed patients.
Report of the case: Here, we report the first Iranian child, an 8-year-old boy, with refractory acute myeloid who
was treated with gemtuzumab ozogamicin. Unfortunately, remission was not achieved and the patient died of
neutropenia and septic shock.
Conclusion: Gemtuzumab ozogamicin therapy in our case was not successful in achieving remission. It could be due
to longstanding chemotherapy and its detrimental effects on bone marrow of the patient. Further controlled studies
are necessary to learn more about efficacy and safety of this new treatment.
Keywords: Childhood acute myeloid leukemia, refractory, treatment, gemtuzumab ozogamicin
:
Original Article |
Subject:
Pediatric Hematology & Oncology Received: 2012/10/10 | Accepted: 2013/01/16 | Published: 2013/07/30